Treatment of early-stage HER2+ breast cancer-an evolving field

被引：8
|
作者：
Ferreira, Arlindo R. [1 ,2 ,3 ]
Saini, Kamal S. [4 ]
Metzger-Filho, Otto [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02215 USA
[2] Univ Lisbon, Hosp Santa Maria, P-1649035 Lisbon, Portugal
[3] Univ Lisbon, Inst Med Mol, P-1649035 Lisbon, Portugal
[4] Univ Libre Bruxelles, Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
ECANCERMEDICALSCIENCE | 2015年 / 9卷
关键词：
breast neoplasm; trastuzumab; neoadjuvant therapy; adjuvant therapy; antibodies; monoclonal; humanised;
D O I：
10.3332/ecancer.2015.523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The evolving field of HER2-targeted therapy has significantly improved the outcome of women diagnosed with HER2-positive invasive breast cancer. In this review, we sought to summarise the efficacy of trastuzumab-based regimens in the adjuvant and neoadjuvant setting with a special emphasis on relevant clinical questions: treatment duration, sequence of trastuzumab administration, toxicity, the role of anthracycline-based regimens, and optimal management of small HER2+ tumours. Controversial topics are discussed taking into consideration the development of modern anti-HER2 agents.
引用
收藏
页数：15
相关论文
共 50 条
  • [41] Institutional variations in the treatment of early-stage breast cancer
    Nayyar, Apoorve
    Strassle, Paula
    Iles, Kathleen
    Jameison, Danielle
    McGuire, Kandace
    Gallagher, Kristalyn
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 218 - 219
  • [42] Treatment of early-stage breast cancer in elderly women
    Harris, EER
    Solin, LJ
    MEDICAL AND PEDIATRIC ONCOLOGY, 2000, 34 (01): : 48 - 52
  • [43] The Cost of Simplicity for Early-stage Breast Cancer Treatment
    Vicini, Frank
    Livi, Lorenzo
    Pignol, Jean-Philippe
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (01): : 1 - 1
  • [44] Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
    Rupert Bartsch
    Simon Peter Gampenrieder
    Gabriel Rinnerthaler
    Edgar Petru
    Daniel Egle
    Andreas Petzer
    Marija Balic
    Ursula Pluschnig
    Thamer Sliwa
    Christian Singer
    Wiener klinische Wochenschrift, 2022, 134 : 63 - 72
  • [45] Adjuvant therapy of HER2+ breast cancer
    EP Winer
    Breast Cancer Research, 11
  • [46] HER2+ breast cancer: How to evaluate?
    Schmitt F.
    Advances in Therapy, 2009, 26 (Suppl 1) : S1 - S8
  • [47] Genomic copy number alterations (CNA) associated with pCR in HER2-positive (HER2+) early-stage breast cancer (BrCa) patients receiving neoadjuvant trastuzumab (T)
    Walsh, N.
    Gullo, G.
    Maguire, A.
    O'Donovan, N.
    Quinn, C.
    Crown, J.
    CANCER RESEARCH, 2017, 77
  • [48] HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
    Xu, Luying
    Xie, Yuxin
    Gou, Qiheng
    Cai, Rui
    Bao, Rong
    Huang, Yucheng
    Tang, Ruisi
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [49] Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial
    Braso-Maristany, F.
    Martinez Saez, O.
    Pare Brunet, L.
    Marin-Aguilera, M.
    Conte, P. F.
    Jares, P.
    Guarneri, V.
    Pascual, T.
    Puig-Butille, J. A.
    Vivancos, A.
    Parker, J.
    Villagrasa Gonzalez, P.
    Tolaney, S. M.
    Carey, L. A.
    Perou, C. M.
    Prat, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S134 - S135
  • [50] Adjuvant therapy of HER2+ breast cancer
    Winer, E. P.
    BREAST CANCER RESEARCH, 2009, 11 : S6 - S6
12345